Published in Vaccine Weekly, June 3rd, 2009
Toronto’s Arius Research, that made headlines last year in an all cash acquisition deal from Roche worth C$191 million, took top honours as company of the year. “With this significant deal with a major global pharmaceutical player, Arius is a successful example of the globally recognized leadership of Canadian private sector biotechnology research,” said BIOTECanada Chairman, Brad Thompson.
The early...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2009-06-03)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.